EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH

View source ↗

Summary

Authorised status for Zarzio (filgrastim) by Sandoz GmbH in the EU, covering hematopoietic stem cell transplantation and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Zarzio® (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Sandoz GmbH. Decision date: 20/03/2025